Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
Kenneth B. Gordon, Richard Langley, Richard B. Warren, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 4, pp. 477-485
Open Access | Times Cited: 18

Showing 18 citing articles:

Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period
Richard B. Warren, Mark Lebwohl, Diamant Thaçi, et al.
British Journal of Dermatology (2025)
Closed Access | Times Cited: 1
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials
Andrew Blauvelt, April W. Armstrong, Joseph F. Merola, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 1, pp. 72-81
Open Access | Times Cited: 4
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events
Mark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
Dermatology and Therapy (2025)
Open Access
IL-23 blockade in a patient with psoriasis and Toxoplasma gondii reactivation history: Case report and review
Jason Dagher, Julien Ringuet
SAGE Open Medical Case Reports (2025) Vol. 13
Open Access
Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector
Michael Sebastian, Jerry Bagel, Bengt Hoepken, et al.
Dermatology and Therapy (2025)
Open Access
The Role of IL-17A in Mediating Inflammatory Responses and Progression of Neurodegenerative Diseases
Miaoyan Zheng, Lianzhong Luo
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2505-2505
Open Access
Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting
Natalia Rompoti, Irene Stefanaki, Pantelis Panagakis, et al.
Archives of Dermatological Research (2024) Vol. 316, Iss. 5
Closed Access | Times Cited: 3
A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs
Rebecca R Reese, Shiva Ram Nanavath, Jennifer L. Martin, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Challenging case of tinea corporis and faciei in psoriatic patient treated with bimekizumab: the usefulness of mycological screening before biological therapies
Terenzio Cosio, Ruslana Gaeta Shumak, Cristiana Borselli, et al.
Medical Mycology Case Reports (2024) Vol. 46, pp. 100683-100683
Open Access | Times Cited: 1
Putting Data into Practice: A Review of Phase III and Long-Term Efficacy Data for Bimekizumab for Plaque Psoriasis.
Jacob Beer, Sarah Hermak, Omar Noor
PubMed (2024) Vol. 17, Iss. 5 Suppl 2, pp. S7-S10
Closed Access
Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo‐controlled, double‐blinded study
Sang Woong Youn, Seong Jin Jo, Chul Jong Park, et al.
The Journal of Dermatology (2024)
Open Access
Real-World Experience of Bimekizumab in an Elderly Patients Cohort with Plaque-Type Psoriasis: A 24-Week Retrospective Study
Zeno Fratton, Vincenzo Maione, Stefano Bighetti, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 2177-2181
Open Access
Evaluating bimekizumab safety
Katie Lovell, Steven R. Feldman
British Journal of Dermatology (2023) Vol. 190, Iss. 4, pp. 458-459
Closed Access | Times Cited: 1
Evaluating the Efficacy and Safety of Bimekizumab for Plaque Psoriasis and Psoriatic Arthritis: An Expert Consensus Panel Report
Danny Zakria, Lauren E. Miller, T Y Chao, et al.
SKIN The Journal of Cutaneous Medicine (2024) Vol. 8, Iss. 2, pp. 1348-1364
Open Access
Review of dermatologic drugs relevant to inflammatory bowel disease
Katlyn M Smaha, Silas M. Money, Loretta S. Davis
JAAD reviews. (2024) Vol. 1, pp. 65-71
Closed Access
Treatment-emergent candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with Ixekizumab: an integrated safety analysis of 25 clinical studies
Sergio Schwartzman, L. Puig, Arnon D. Cohen, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Open Access
Bimekizumab: A novel FDA approved dual IL-17 A/F inhibitor for moderate to severe psoriasis
Febin Ashraf, Simin Muhammed Kutty
Indian Journal of Dermatology Venereology and Leprology (2024), pp. 1-5
Open Access
Page 1

Scroll to top